XML 123 R77.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Restructuring costs and similar items (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Analysis of income and expense [abstract] |
Summary of Restructuring Costs and Similar Items | Restructuring costs and similar items amounted to €1,490 million in 2023, €1,336 million in 2022 and €820 million in 2021, and were comprised of the following items:
(€ million) | 2023 | 2022 |  | 2021 |
Employee-related expenses | 489 |  | 507 |  |  | 193 |  |
Charges, gains or losses on assets(a) | 293 |  | 261 |  |  | 110 |  |
Costs related to transformation programs | 676 |  | 547 |  |  | 463 |  |
Other | 32 |  | 21 |  |  | 54 |  |
Total | 1,490 |  | 1,336 |  |  | 820 |  |
(a) This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.

X
- References No definition available. + Details
Name: | ifrs-full_AnalysisOfIncomeAndExpenseAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of restructuring costs details. + References No definition available. + Details
Name: | sny_DisclosureOfRestructuringCostsDetailsTableTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration